CLINICAL_TRIALS
trial_result
· 2019-07-09
Clinical Trial Update: Continuation Study of the Oral AKT Inhibitor GSK2110183 [Phase 2]
Summary
Phase 2 continuation study of the oral AKT inhibitor GSK2110183 has completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-07-09